Q 4 A N D F U L L Y E A R 2 0 2 0 P E R F O R M A N C E $0.30 $0.52 2019 PF 2020 Q4 2020 ORGANIC PERFORMANCE 9 Sales $922 $997 2019 PF 2020 +8% Adjusted Operating Income Adjusted EPS $58 $80 2019 PF 2020 +38% +73% • Record 4th quarter sales, adjusted operating income and adjusted EPS performance • All segments delivered year-over-year sales and operating income growth, led by consumer and healthcare end markets • Clariant Masterbatch integration synergy capture ahead of schedule: $5 million realized in 2020 ($ in millions except EPS) (1) (1) (1) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition Q4 2020 SEGMENT PERFORMANCE 10 Sales Operating Income $100 $100 $100 $922 $100 $100 $100 $997 Distribution CAI SEM Total 2019 2020 $178 $272 $490 $191 $305 $526 SEM Distribution CAI 2019PF 2020 +8% +7% +7% +12% $5 $5 $5 $58 $5 $5 $5 $80 Avient CAI SEM Total 2019 PF 2020 $17 $19 $40 $18 $30 $58 Distribution SEM CAI 2019PF 2020 +38% +45% +58% +6% (3) (3) ($ in millions) (1) (2) (1) Total company sales include intercompany sales eliminations (2) Total company reflects adjusted operating income and includes corporate costs (3) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition 2020 HIGHLIGHTS 11 • Completed transformational Clariant Masterbatch acquisition and created new brand name Avient • Increased pro forma adjusted EPS 11% from $1.74 to $1.93 as an essential supplier during the pandemic and due to growth in demand for consumer applications • Specialty Engineered Materials delivered record operating income on gains from composites • Achieved record free cash flow, increased dividend for 10th year in a row and delevered from 3.5x to 2.7x net debt to pro forma adjusted EBITDA • Culture is everything: Certified as a Great Place to Work® $133 $150 2019PF 2020PF 10% 23%8% 21% 4% 15% 2006 2020PF Healthcare Consumer Packaging Avient Portfolio Transformation 22% 59% CLARIANT MASTERBATCH: TRANSFORMATIONAL ACQUISITION 12 Clariant MB EBITDA Growth Purchase Price Multiple 10.8 9.6 6.5 2019PF 2020PF 2020PF w/ Full Synergies x x x • Acquisition of Clariant Masterbatch significantly expands presence in healthcare, packaging and consumer end markets • Strength of portfolio – 13% EBITDA growth as an essential supplier in COVID response and recovery • Acquisition completed on July 1, 2020 for $1.4 billion. 16 2 0 2 1 O U T L O O K Synergies ($ millions) Initial Three-Year Estimate Revised Three-Year Estimate 2021 Expected Realization Administrative $ 18 $ 20 $ 15 Sourcing 24 30 15 Operational 18 25 5 Total Synergies $ 60 $ 75 $ 35 C L A R I A N T I N T E G R AT I O N & C O S T S Y N ERG I E S U PDATE 18 • Integration going extremely well: synergy target increased from $60 million to $75 million • $5 million of synergies in 2020 and expect to realize $35 million in 2021 • Relentless focus on guiding principles of safety first, employee collaboration and exceeding customer expectations • Future revenue synergies are not part of these estimates and represent additional growth over the long term $86 $103 2020PF 2021E $0.53 $0.70 2020PF 2021E ORGANIC GROWTH PROJECTIONS – Q1 ( T O TA L C O M PA N Y ) 19 Sales Adjusted Operating Income $991 $1,090 2020PF 2021E + 10% Adjusted EPS + 20% + 32% (in millions) (in millions) (1) (1) (1) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition $308 $360 2020PF 2021E $1.93 $2.40 2020PF 2021E ORGANIC GROWTH PROJECTIONS – FULL YEAR ( T O TA L C O M PA N Y ) 20 Sales Adjusted Operating Income $3,783 $4,100 2020PF 2021E + 8% Adjusted EPS + 17% + 24% (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (1) (1) (in millions) (in millions) (1) 2020 Pro forma $3,783 $308 Sustainable Solutions 60 11% 24 Healthcare 60 11% 18 Composites 20 10% 10 Growth in Emerging Regions 50 7% 11 Other (GDP growth) 82 5% 11 Sub-total $4,055 7% $382 COVID Response Applications (25) - (11) Outdoor High Performance Applications (15) - (7) Asia Payroll Tax Subsidy (COVID) - - (4) FX Impact 85 - 7 Synergies - - 30 Incentives, Travel, Other Employee Costs - - (37) 2021 Estimated $4,100 8% $360 2021 ORGANIC SALES AND OPERATING INCOME ( T O TA L C O M PA N Y ) 21 (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (2) COVID Response Applications: facemasks, personal protective equipment Sales Growth Rate Adjusted Operating Income$ millions (1) (2) C A S H F LOW A N D L E V E R AGE 22 • Asset light business generates significant free cash flow • Cash generation in 2021 partially offset by restructuring activities to capture synergies associated with the Clariant Masterbatch acquisition • Cash flow deployed to M&A, opportunistic share repurchases and balance sheet / leverage reduction 3.5x 2.7x 2.1x 2019PF 2020PF 2021E Net Debt / Adjusted EBITDA (1) (1) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition ($ millions) 2020 2021E Adjusted EBITDA 382 510 Working Capital: Source / (Use) 116 (30) Cash Taxes (40) (53) Interest Paid (67) (76) CapEx (62) (75) CapEx for Synergy Capture (2) (20) Restructuring for Synergy Capture (11) (25) Other 22 19 Free Cash Flow 338 250 23 • 8% increase in sales drives 24% increase in adjusted EPS to $2.40 ($2.70 excluding step-up depreciation and amortization) as a result of continued growth in sustainable solutions and synergy capture • Clariant synergy capture ahead of schedule: $35M of savings planned from Clariant Masterbatch acquisition • Adjusted EBITDA of $510M – highest level in company history • Deleveraging ahead of schedule – 2.1x net debt to adjusted EBITDA by the end of 2021 2021 PROJECTIONS PEER COMPARISONS 24 As a specialty formulator, we don’t require significant capital investment, as compared to the base resin raw material suppliers we purchase from. SEGMENT HIGHLIGHTS U.S. & Canada 50% EMEA 26% Asia 16% Latin America 8% 2020 SEGMENT, END MARKET AND GEOGRAPHY 30 GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 23% Packaging 21%Industrial 15% Wire & Cable 6% Building & Construction 6% Electrical & Electronics 4% END MARKET REVENUE Transportation 10% Healthcare 15% All data reflects 2020 Pro forma for acquisition of the Clariant Masterbatch business. (1) The total company sales and EBITDA of $3,783M and $457M, respectively, include intercompany sales eliminations and corporate costs $2,043M $331M $709M $124M $1,110M $70M Sales EBITDA Distribution Specialty Engineered Materials Color Additives and Inks $457M$3,783M (1) Packaging 35% Consumer 23% Healthcare 8% Industrial 14% Building & Construction 8% Transportation 7% Wire & Cable 3% Electrical & Electronics 2% C O L O R , A D D I T I V E S & I N K S 2 0 2 0 P F R E V E N U E | $ 2 . 0 B I L L I O N US & Canada 31% EMEA 40% Asia 22% Latin America 7% END MARKET REGION 31 2020 figures Pro forma for acquisition of the Clariant Masterbatch business S P E C I A L T Y E N G I N E E R E D M A T E R I A L S Consumer 24% Healthcare 10% Packaging 6% Wire & Cable(1) 24% Electrical & Electronics 13% Transporation 11% Industrial 10% Building & Construction 2% 2 0 2 0 R E V E N U E | $ 7 0 9 M I L L I O N END MARKET US & Canada 58% EMEA 23% Asia 19% REGION 32 (1) Approximately 50% of Wire and Cable sales are associated with Fiber Optic Cabling D I S T R I B U T I O N 2 0 2 0 R E V E N U E | $ 1 . 1 B I L L I O N Healthcare 29% Consumer 25% Packaging 2% Industrial 20% Transportation 14% Electrical & Electronics 5% Building & Construction 4% Wire & Cable 1% US & Canada 82% Asia 3% Latin America 15% END MARKET REGION K E Y S U P P L I E R S 33 AMERICAS EMEA ASIA Consumer 26% Healthcare 19% Packaging 13% Industrial 16% Wire & Cable 7% Building & Construction 5% Electrical & Electronics 4% Packaging 34% Consumer 16%Healthcare 5% Industrial 17% Wire & Cable 10% Building & Construction 8% Electrical & Electronics 3% Packaging 32% Consumer 27% Healthcare 12% Industrial 6% Wire & Cable 6% Building & Construction 4% Electrical & Electronics 9% Transportation 10% Transportation 7% Transportation 4% 2020 figures Pro forma for acquisition of the Clariant Masterbatch business T O T A L C O M PA N Y R E G I O N A L S A L E S B Y E N D M A R K E T (58% of sales) (26% of sales) (16% of sales) 34 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

PAYMENTS Unless otherwise directed or agreed to by Seller, all invoices are payable thirty (30) days after the date of invoice. FIZETÈSEK Amennyiben más megállapodás vagy rendelkezés nincs Eladóval, minden számlát a kiállítástól számított harminc (30) napon belül kell megfizetni. PRICE AND TERMS ADJUSTMENT Seller may change any price, freight term and/or term of payment by giving Buyer thirty (30) days prior written notice.

Avient Corporation 1 J E F F E R I E S V I R T U A L I N D U S T R I A L S C O N F E R E N C E A U G U S T 2 0 2 0 Avient Corporation 2 FORWARD LOOKING STATEMENTS • • • • • • • • • • • • • • • • • • • • Avient Corporation 3 U S E O F N O N - G A A P M E A S U R E S • • • Avient Corporation 4 U P D A T E O N T H E C O V I D - 1 9 P A N D E M I C • • • • Avient Corporation 5 2019 Transportation Consumer Discretionary Healthcare Packaging All Other Industries Cost Containment FX 2020 $64.3 18% 18% 9% 6% 16% 2% $46.9 20% • • • • • • S E C O N D Q U A R T E R 2 0 2 0 I N R E V I E W Consumer Discretionary Avient Corporation 6 CLARIANT MASTERBATCH STRATEGIC RATIONALE Avient Corporation 7 F I T W I T H F O U R P I L L A R S T R A T E G Y Specialization • • • Globalization • • Operational Excellence • • • Commercial Excellence • • People Avient Corporation 8 5% 2006 2019E PF* 4% 12% 10% 18% 8% 20% 2006 2019E PF* Healthcare Consumer Packaging 38% * 2019E Pro Forma for PP&S Divestiture and Clariant Masterbatch business Percentage of Total Revenue E N D M A R K E T T R A N S F O R M A T I O N Building & Construction High Growth End Markets 50% 22% Avient Corporation 9 Wire & Cable 11% Industrial 10% Electrical & Electronic 7% Healthcare 4% Packaging 8% Consumer 10% Transportation 12% Building & Construction 38% Healthcare 12% Packaging 20% Consumer 18%Transportation 12% Building & Constrution 5% Wire & Cable 9% Industrial 11% Electrial & Electronic 4% Appliance 2% Textiles 7% 2006 Pro Forma(1) Net Sales by End Market E N D M A R K E T T R A N S F O R M A T I O N Avient Corporation 10 U N I F I E D F O C U S O N S U S T A I N A B I L I T Y 2006 - 2013 2013 – 2019 P E O P L E P R O D U C T S P L A N E T P E R F O R M A N C E •• •• •• Avient Corporation 11 O V E R 8 5 % O F A D J U S T E D E B I T D A F R O M S P E C I A L T Y 46% 66% 0% 20% 40% 60% 80% 100% 2005 2010 2015 Pro Forma % o f A d ju s t e d E B IT D A ( 1 ) JVs Performance Products & Solutions Distribution Specialty 7% 87% (2) Avient Corporation 12 T H E N E W A V I E N T : A S P E C I A L T Y G R O W T H C O M P A N Y     Transaction expected to add $0.85 to pro forma adjusted EPS Avient Corporation 13 SUSTAINABILITY AT AVIENT P E O P L E , P R O D U C T S , P L A N E T , P E R F O R M A N C E Avient Corporation 13 Avient Corporation 14 V I S I O N To be the world’s premier provider of specialized polymer materials, services and solutions C O R E V A L U E S P E R S O N A L V A L U E S Honesty IntegrityRespect Operational Excellence Commercial Excellence Specialization Globalization Collaboration ExcellenceInnovation To be the world’s premier provider of specialized polymer materials, services and sustainable solutions Avient Corporation 15 1.3 1.1 1.1 0.85 0.65 0.57 0.54 0.97 0.84 0.74 0.74 0.69 0.51 0.56 0.14 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 YTD S A F E T Y F I R S T Injuries per 100 Workers Spartech Acquisition Avient Corporation 16 G R E A T P L A C E T O W O R K Avient Corporation 17 C O M M O D I T Y T O S P E C I A L T Y T R A N S F O R M A T I O N • • • • • • • • • • • • 2006 - 2013 2013 – 20192000-2005 2006 - 2013 • • 2020 and Beyond Avient Corporation 18 A V I E N T 2 0 1 9 R E V E N U E | $ 2 . 9 B I L L I O N Segment End Market Geography Healthcare 15% Industrial 14% Consumer 14% Packaging 13% Transportation 13% Wire & Cable 11% Building & Construction 6% Electrical & Electronics 6% Textiles 5% Appliance 3% Color Additives & Inks 34% Distribution 41% Specialty Engineered Materials 25% United States 54% Europe 19% Asia 11% Latin America 11% Canada 5% Avient Corporation 19 Operating Income % of Sales 2006 2019 Color, Additives & Inks 1.7% 14.7% Specialty Engineered Materials 1.1% 11.6% Distribution 2.6% 6.3% 2009 2010 2011 2012 2013 2014 2015 2016* 2017* 2018 $2.43 P R O O F O F P E R F O R M A N C E C O N S E C U T I V E Y E A R S 1 0 $0.13 $0.68 $0.82 $1.00 $1.31 $1.80 $1.96 $2.06 $2.21 A D J U S T E D E P S E X P A N S I O N 2018 2019 $1.69 $1.51 Avient Corporation 20 531 710 1,032 130 164 207 504 663 871 2014 2018 Pro Forma R&D / Technical Marketing Sales + 34% + 26% + 32% E X P A N S I O N O F C O M M E R C I A L R E S O U R C E S D R I V I N G G R O W T H Revenue in Billions Total + 10% Organic + 7%+ 45% + 26% + 31% $4.0 $3.2 (2) (1) (1) $2.9 $2.9 $3.5 2015 2016 2017 2018 Pro Forma Total + 9% Organic + 5% Pro Forma(2) Avient Corporation 21 P R I O R A C Q U I S I T I O N S H I S T O R Y Commercial Resources(1) Operating Income ($ in millions) Operating Margins 256 350 At Acquisition 2019 $36 $100 At Acquisition 2019 9% 19% At Acquisition 2019 Established Acquisitions (> 7 years) + 37% + 176% + 1000 bps Avient Corporation 22 A L I G N I N G W I T H T R E N D S F O R G R O W T H T R A N S P O R T A T I O N P A C K A G I N G H E A L T H C A R E C O N S U M E R Facilitate alternative energy solutions Light- weighting Reduce packaging materials Improve recyclability Reduce spread of infection Avient Corporation 23 I N N O V A T I O N Customization 55% M&A 30% Innovation Pipeline 15% Innovation comes from Research & Development Spend Vitality Index 12% 37% 2006 2019 $20 $51 2006 2019 Avient Corporation 24 R E V E N U E F R O M S U S T A I N A B L E S O L U T I O N S $275M $325M $355M $410M 14% Total Annual Growth 9% Organic Annual Growth Avient Corporation 25 SEGMENT HIGHLIGHTS I N N O V A T I N G W I T H A V I E N T Avient Corporation 25 Avient Corporation 26 C O L O R , A D D I T I V E S & I N K S E N D M A R K E T S & S O L U T I O N S Solid Colorants Performance Additives Screen Printing Inks Liquid Colorants Packaging 31% Industrial 14% Textiles 13% Wire & Cable 10% Building & Construction 9% Consumer 8% Transportation 7% Healthcare 5% Appliances 2% Electrical & Electronics 1% Avient Corporation 26 Avient Corporation 27 Operating Income & MarginRevenue by Region C O L O R , A D D I T I V E S & I N K S 2 0 1 9 R E V E N U E | O V E R $ 1 B I L L I O N Europe 34% United States 44% Asia 15% Canada 1% Mexico 3% South America 3% $4 $25 $104 $147 2005 2009 2013 2019 0.9% 5.5% 12.2% 14.7% Avient Corporation 27 Avient Corporation 28 S P E C I A L T Y E N G I N E E R E D M A T E R I A L S E N D M A R K E T S & S O L U T I O N S Engineered Formulations Advanced Composites Thermoplastic Elastomers Wire & Cable* 28% Consumer 19% Electrical & Electronics 12% Healthcare 9% Industrial 8% Packaging 6% Appliance 2% Building & Construction 2% Transportation 14% Avient Corporation 28 Avient Corporation 29 S P E C I A L T Y E N G I N E E R E D M A T E R I A L S Revenue by Region Operating Income & Margin 2 0 1 9 R E V E N U E | $ 7 5 0 M I L L I O N Europe 27% United States 54% Asia 17% Canada 2% $21 $57 $87 2005 2009 2013 2019 0.1% 5.1% 9.3% 11.6% Avient Corporation 29 Avient Corporation 30 D I S T R I B U T I O N E N D M A R K E T S & S U P P L I E R S Healthcare 28% Industrial 19% Transportation 18% Consumer 17% Appliance 6% Electrical & Electronics 5% Building & Construction 4% Packaging 2% Wire & Cable 1% Operating Income & Margin2019 Revenue | $1.2 Billion $25 $63 $75 2005 2009 2013 2019 $20 2.9% 4.0% 5.9% 6.3% Avient Corporation 30 http://www.polyone.com/Pages/VariationRoot.aspx Avient Corporation 31 O V E R V I E W O F R A W M A T E R I A L P U R C H A S E S Avient Corporation 31 Avient Corporation 32 Avient Corporation 33 Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016** 2017** 2018 2018*** Q1 2019*** 2019 Q1 2020 Net income from continuing operations attributable to PolyOne common shareholders Joint venture equity earnings, after tax Special items, before tax (1) Special items, tax adjustments (1) Adjusted net income from continuing operations attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1 $ 87.7 $ 22.4 $ 75.5 $ 33.1 (19.0) (14.7) (3.7) — — — — — — — — — — — (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5 58.7 12.2 61.7 9.6 (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3) (25.1) (1.2) (5.9) (1.0) $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3 $ 121.3 $ 33.4 $ 131.3 $ 41.7 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4 80.4 78.2 77.7 86.7 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43 $ 1.51 $ 0.43 $ 1.69 $ 0.48 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation. ** Pro forma for sale of Designed Structures and Solutions segment (DSS). *** Pro forma for sale of Performance Products and Solutions segment (PP&S). Reconciliation to Adjusted EPS Excluding Special Items and Impacts of February 2020 Equity Offering and May 2020 Debt Offering Three Months Ended June 30, 2020 Net income from continuing operations attributable to Avient common shareholders $ 23.0 Special items, after tax(1) 2.6 After tax interest expense, net arising from equity offering and debt offering proceeds 4.1 Adjusted net income excluding special items and impact of interest expense, net arising from equity offering and debt offering proceeds $ 29.7 Diluted weighted-average shares used to compute earnings per common share 91.8 Weighted-average impact of 15.3 million shares issued in February 2020 equity offering (15.3) Diluted weighted-average shares excluding impact of shares issued in February 2020 equity offering 76.5 Adjusted EPS excluding special items and impact of equity offering and debt offering $ 0.39 (1) Special items include charges related to specific strategic initiatives or financial restructuring such as: consolidation of operations; debt extinguishment costs; costs incurred directly in relation to acquisitions or divestitures, including adjustments related to contingent consideration; employee separation costs resulting from personnel reduction programs, plant realignment costs, executive separation agreements; asset impairments; settlement gains or losses and mark-to-market adjustments associated with actuarial gains and losses on pension and other post-retirement benefit plans; environmental remediation costs, fines, penalties and related insurance recoveries related to facilities no longer owned or closed in prior years; gains and losses on the divestiture of operating businesses, joint ventures and equity investments; gains and losses on facility or property sales or disposals; results of litigation, fines or penalties, where such litigation (or action relating to the fines or penalties) arose prior to the commencement of the performance period; one-time, non- recurring items; and the effect of changes in accounting principles or other such laws or provisions affecting reported results.

PDI scientists have on average 30 years each in the industry and are ready to take on any challenge. PDI scientists have on average 30 years each in the industry and are ready to take on any challenge.

1)30日以上、人体組織または体液に暴露すること。 3)生殖器用インプラントまたは避妊具、または (4)人間の生命を支え、維持する永久的（30日以上）移植された医療機器の重要な構成要素。

在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。

1)30日以上、人体組織または体液に暴露すること。 3)生殖器用インプラントまたは避妊具、または (4)人間の生命を支え、維持する永久的（30日以上）移植された医療機器の重要な構成要素。

KEY PERFORMANCE PROPERTIES1 PHYSICAL NOMINAL VALUE UNIT TEST METHOD Density/Specific Gravity 1.00 ASTM D792 Melt Mass-Flow Rate (MFR) (230°C/2.16kg) 20 g/10 min ASTM D1238 MECHANICAL Tensile Strength 15.0 MPa ASTM D638 Flexural Modulus 1400 MPa ASTM D790 Flexural Strength 35.0 MPa ASTM D790 IMPACT Notched Izod Impact (Injection Molded) 150 J/m ASTM D256 ELECTRICAL Surface Resistivity < 100000 ohms/sq ASTM D257 PROCESSING INFORMATION INJECTION NOMINAL VALUE UNIT Drying Temperature 80 to 90 °C Drying Time 4.0 to 6.0 hr Processing (Melt) Temperature 220 to 250 °C Mold Temperature 30 to 80 °C Trilliant™ HC Electrically Conductive Formulations for Precision Performance Pipette Tips A critical design consideration for pipette tips is the accurate measurement of finite amounts of liquid.

Better Performance-to-Cost Ratios – Traditionally used materials can cost 30–40% more than a thermoplastic solution at only slightly better performance.

However, most brass flapper valves open only 25–30 percent, preventing the pig from passing through.